{'fraction_non_alphanumeric': 0.06687402799377916, 'fraction_numerical': 0.04043545878693624, 'mean_word_length': 4.902140672782875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hybrid renal replacement therapy can alleviate the metabolic disorder of calcium or phosphate and micro-inflammation in patients undergoing maintenance hemodialysis and treated with 1,25-(OH)-VitD3

Objective To evaluate the effects of hybrid renal replacement therapy (HRRT) on metabolic disorder of calcium or phosphate and micro-inflammation in maintenance hemodialysis (MHD) patients treated with a maintenance dose of 1,25-(OH)VitD3.Methods A total of 42 MHD patients were randomly assigned to group A and group B.Those in group A were treated with hemodialysis,while the subjects in group B were treated with combined hemodialysis-hemoperfusion.All the participants took a maintenance dose of 1,25-(OH)VitD3(0.25 U/d) and were followed up for 4 weeks.The serum levels of serum calcium,phosphorus,intact parathyroid hormone (iPTH) and C-reactive protein (CRP) were detected at baseline and post-treatment.Student' s t test was used for data analysis.Results The level of serum phosphorus was elevated following treatment ((2.2 ± 0.4) vs (2.3 ± 0.5) mmol/L) in group A,although the difference was not statistically significant.In group B,the level of serum phosphorus was significantly decreased post treatment ((2.2±0.6) vs (1.7 ± 0.4) mmol/L,P ＜ 0.05).The serum level of calcium didn' t significantly changed in two groups,while serum iPTH was significantly down regulated after the treatment (group A:(340± 36) vs (310 ± 25) ng/L,P ＜ 0.05; group B:(355 ± 38) vs (285 ± 29) ng/L,P ＜ 0.01).CRP was significantly reduced after HRRT in group B (3.3 ± 4.8) vs (1.5 ± 3.8) mg/L,P ＜ 0.01).Conclusions HRRT can alleviate metabolic disorder of calcium or phosphate and microinflammation in maintenance hemodialysis patients treated with a maintenance dose of 1,25-(OH)VitD3. 
 
Key words: 
Hybrid renal replacement therapy;  Intact parathyroid hormone;  Serum calcium;  Serum phosphorus;  Micro-inflammation;  Maintenance treatment